PRQR News and Press, ProQR Therapeutics N.V. From 11/07/23

Continued advancement of platform and initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease targeting B4GALT1 Further strengthened leading intellectual property (IP) position with issuance of new patent in the United States and...

LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today announced that Dan...

LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies today provided an update that its previously announced agreement to divest the Company’s...

LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today announced that Com...

2023-08-03 10:15:24 ET ProQR press release ( NASDAQ: PRQR ): Q2 GAAP EPS of -€0.10. Revenue of €1.21M (+30.1% Y/Y). €129M cash and cash equivalents as of June 30, 2023 providing runway into mid-2026. Research and development costs were &#x...

Divestment of sepofarsen and ultevursen ophthalmic programs supports ProQR’s strategic focus on Axiomer® RNA editing platform technology and continued advancement of pipeline €129 M cash and cash equivalents as of June 30, 2023 providing runway into mid-2026 LEID...

2023-08-01 11:43:52 ET More on ProQR ProQR: Too Many Failures For Its RNA Technology ProQR adds 75% as Cantor upgrades on expanded deal with Eli Lilly Eli Lilly sends ProQR 35% higher after expanding RNA editing deal AstraZeneca – LogicBio deal indicat...

Agreement provides ProQR with initial payment of €12.5M and up to €135M in further payments, as well as potential additional earn outs based on commercial sales in the US and EU Divestment of sepofarsen and ultevursen supports ProQR’s strategic focus on the Axiomer&...

2023-07-09 06:53:51 ET Summary PRQR, last year, failed a pivotal trial. This is the third time it has failed trials after showing early signs of efficacy. While they are making an effort, I see little future here. In June 2021, I covered ProQR ( PRQR ) when i...

2023-07-09 03:09:09 ET Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Stitcher and Spotify . For further details see: Wall Street Breakfast: The Week Ahead